{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:25:39Z","timestamp":1761560739444},"reference-count":37,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2002,3,21]],"date-time":"2002-03-21T00:00:00Z","timestamp":1016668800000},"content-version":"vor","delay-in-days":48,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Helicobacter"],"published-print":{"date-parts":[[2002,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background.<\/jats:bold> The recently reported OMNIUM and ASTRONAUT NSAID ulcer prevention trials using omeprazole to prevent endoscopic ulcer recurrence among chronic NSAID users suggested superiority over misoprostol or ranitidine.<\/jats:p><jats:p><jats:bold>Aim.<\/jats:bold> To test the hypothesis the results from the OMNIUM and ASTRONAUT studies would not be generalizible as ulcer healing and ulcer recurrence would differ in relation to <jats:italic>Helicobacter pylori<\/jats:italic> status.<\/jats:p><jats:p><jats:bold>Methods.<\/jats:bold> The data regarding <jats:italic>H.\u00a0pylori<\/jats:italic> status were made available by AstraZenca allowing separate analysis of the outcome of those with NASID ulcers (i.e. without <jats:italic>H.\u00a0pylori<\/jats:italic> infection) and those NSAID use was complicated with the presence of an active <jats:italic>H.\u00a0pylori<\/jats:italic> infection.<\/jats:p><jats:p><jats:bold>Results.<\/jats:bold> Reanalysis confirmed that omeprazole was superior to placebo for the prevention of ulcer recurrence in chronic NSAID users. However, overall omeprazole was not significantly better than the subtherapeutic dose (400 \u00b5g\/day) of misoprostol (14.5% vs. 19.6%, respectively, <jats:italic>p<\/jats:italic>\u00a0=\u00a0.93); 400 \u00b5g of misoprostol was actually superior to omeprazole for the prevention of gastric ulcers among those NSAID ulcers (8.2% vs. 16.6% for misoprostol and omeprazole, respectively; <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a0.05). Omeprazole was also not statistically different from misoprostol for gastric ulcer prevention in those whose NSAID use was complicated by an active <jats:italic>H.\u00a0pylori<\/jats:italic> infection. Omeprazole was not significantly different from 300\u00a0mg of ranitidine for the prevention of NSAID gastric ulcers (14.6% vs. 11.6%, respectively, <jats:italic>p<\/jats:italic>\u00a0=\u00a0.56). Duodenal ulcers were over represented among <jats:italic>H.\u00a0pylori<\/jats:italic> infected NSAID users and duodenal ulcer prevention was more sensitive to acid suppression than gastric ulcer.<\/jats:p><jats:p><jats:bold>Conclusion.<\/jats:bold> The OMNIUM and ASTRONAUT trials may have provided an unrealistic sense of security regarding the effectiveness of omeprazole for protection against ulcer recurrence in chronic NSAID users.<\/jats:p>","DOI":"10.1046\/j.1523-5378.2002.00048.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T23:22:47Z","timestamp":1047424967000},"page":"1-8","source":"Crossref","is-referenced-by-count":26,"title":["Critical Effect of <i>Helicobacter pylori<\/i> Infection on the Effectiveness of Omeprazole for Prevention of Gastric or Duodenal Ulcers Among Chronic NSAID Users"],"prefix":"10.1111","volume":"7","author":[{"given":"David Y.","family":"Graham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,3,21]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803123381105"},{"key":"e_1_2_10_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803123381104"},{"key":"e_1_2_10_4_2","volume-title":"The Basics of Evidence Based Medicine","author":"Greenhalgh T.","year":"1997"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.297.6655.1017"},{"key":"e_1_2_10_6_2","first-page":"223","article-title":"Misoprostol and ranitidine in the prevention of NSAID\u2010induced ulcers: a prospective, double\u2010blind, multicenter study","volume":"91","author":"Raskin JB","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01536266"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0953-0673.1996.00347.x"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-5-199509010-00004"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199605303342204"},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v112.pm9178671"},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v112.agast972143"},{"key":"e_1_2_10_13_2","first-page":"1644","article-title":"A dose ranging study of famotidine in prevention of gastroduodenal lesions associated with non\u2010steroidal anti\u2010inflammatory drugs (NSAIDs): results of a US multicenter trial","volume":"89","author":"Simon TJ","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00434.x"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-4-199508150-00001"},{"key":"e_1_2_10_16_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-1999-13672"},{"key":"e_1_2_10_17_2","unstructured":"GrahamDY AgrawalNM CampbellDR HaberMM et\u00a0al.Ulcer Prevention in Chronic NSAID Users: Results of a double\u2010blind randomized multicenter active\u2010 and placebo\u2010controlled study of misoprostol vs. lansoprazole.Arch Intern Med2002 in press."},{"key":"e_1_2_10_18_2","first-page":"2080","article-title":"Nonsteroidal anti\u2010inflammatory drugs, Helicobacter pylori, and ulcers: where we stand","volume":"91","author":"Graham DY.","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_10_19_2","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1001\/archinte.1996.00440130066007","article-title":"Gastrointestinal tract complications of nonsteroidal anti\u2010inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study","volume":"156","author":"Singh G","year":"1996","journal-title":"Arch Intern Med"},{"key":"e_1_2_10_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199906173402407"},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529609010347"},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04206-8"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.39.1.22"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529708996515"},{"key":"e_1_2_10_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)70075-1"},{"key":"e_1_2_10_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.475"},{"key":"e_1_2_10_27_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v110.pm8608881"},{"key":"e_1_2_10_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70120-4"},{"key":"e_1_2_10_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)92892-9"},{"key":"e_1_2_10_30_2","doi-asserted-by":"publisher","DOI":"10.3109\/03009749409103056"},{"key":"e_1_2_10_31_2","first-page":"271","article-title":"Elimination of Helicobacter pylori under treatment with omeprazole","volume":"28","author":"Stolte M","year":"1990","journal-title":"Z Gastroenterol"},{"key":"e_1_2_10_32_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-3-199408010-00001"},{"key":"e_1_2_10_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)90344-C"},{"key":"e_1_2_10_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00370.x"},{"key":"e_1_2_10_35_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.00196.x"},{"key":"e_1_2_10_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199604183341603"},{"key":"e_1_2_10_37_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1004278"},{"key":"e_1_2_10_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)04523-6"}],"container-title":["Helicobacter"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1523-5378.2002.00048.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1523-5378.2002.00048.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T16:48:30Z","timestamp":1697561310000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1523-5378.2002.00048.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["10.1046\/j.1523-5378.2002.00048.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1523-5378.2002.00048.x","archive":["Portico"],"relation":{},"ISSN":["1083-4389","1523-5378"],"issn-type":[{"value":"1083-4389","type":"print"},{"value":"1523-5378","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2]]}}}